(Investorideas.com Newswire) a go-to platform for big investing ideas, including  biotech stocks issues a news and trading alert for Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases. The stock makes the Nasdaq top gainer list on news today, currently trading at $1.5300, up 0.6310 on over 38 Million shares as of this report. The stock has a morning  high of $1.60. Edesa Biotech announced today p ...

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2025 and provided an update on its business. During the first quarter, Edesa progressed manufacturing of its dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), and placebo for an upcoming Phase 2 study in moderate-t ...

Core Insights - Edesa Biotech, Inc. reported financial results for the fiscal year ended September 30, 2025, highlighting advancements in its clinical programs and financial performance [1][4]. Financial Performance - Total operating expenses increased by $0.9 million to $7.9 million for the year ended September 30, 2025, compared to $7.0 million for the prior year [4]. - Edesa reported a net loss of $7.2 million, or $1.27 per common share, compared to a net loss of $6.2 million, or $1.93 per common share, for the year ended September 30, 2024 [5]. - Cash and cash equivalents at September 30, 2025, were $10.8 million, with working capital of $10.4 million [6]. Clinical Developments - The company initiated manufacturing activities for a Phase 2 study of EB06, an anti-CXCL10 monoclonal antibody, targeting moderate-to-severe nonsegmental vitiligo, with recruitment expected to begin by mid-2026 [2]. - A Phase 3 study of paridiprubart (EB05) met primary and secondary endpoints with statistical significance, and the company is exploring partnerships for its development and commercialization [2][3]. Strategic Initiatives - Edesa's CEO emphasized the company's strategy to advance both dermatology and respiratory assets, aiming to deliver transformative therapies to patients with high unmet medical needs [3]. - The CFO noted that the company strengthened its balance sheet and extended its Canadian government funding agreement to support manufacturing and development for its respiratory program [3]. Research and Development Expenses - Research and development expenses increased by $0.8 million to $3.7 million for the year ended September 30, 2025, primarily due to increased manufacturing-related activities and preparations for the Phase 2 clinical study of EB06 [7]. - General and administrative expenses rose by $0.1 million to $4.2 million, mainly due to increased noncash share-based compensation [7]. Future Outlook - Edesa plans to participate in one-on-one meetings during JP Morgan week starting January 12, 2026, to engage with potential strategic and government partners [7].

Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical-stage biopharmaceutical development, particularly focusing on its vitiligo drug candidate EB06, while reporting financial results that reflect a strategic pivot in operational activities towards this program [1][4]. Financial Overview - For the three months ended March 31, 2025, total operating expenses decreased by $0.6 million to $1.6 million compared to $2.2 million for the same period in 2024 [7] - The company reported a net loss of $1.6 million, or $0.30 per common share, for the quarter, an improvement from a net loss of $1.9 million, or $0.58 per common share, for the same quarter last year [8] - For the six months ended March 31, 2025, total operating expenses decreased by $0.6 million to $3.5 million compared to $4.1 million for the same period in 2024 [9] - The net loss for the six months was $3.2 million, or $0.74 per common share, compared to a net loss of $3.5 million, or $1.12 per common share, for the same period last year [11] Business Development - The company completed a $15 million equity financing to support the development of EB06, an anti-CXCL10 monoclonal antibody for vitiligo [2] - Edesa has initiated outreach to potential investigators and manufacturing activities to support U.S. regulatory approval for a Phase 2 study in moderate-to-severe nonsegmental vitiligo patients [2][6] - The planned Phase 2 study for EB06 is already approved in Canada, with drug manufacturing data expected to be submitted to the FDA in the second half of 2025 [6] Research and Development - Research and development expenses decreased by $0.7 million to $0.5 million for the three months ended March 31, 2025, primarily due to decreased external research expenses related to the investigational drug paridiprubart [9][16] - General and administrative expenses increased by $0.2 million to $1.2 million for the three months ended March 31, 2025, mainly due to increased salaries and related costs [9] Cash Position - As of March 31, 2025, Edesa had cash and cash equivalents of $13.9 million and working capital of $13.5 million [12]